Titan Biotech Ltd
Titan Biotech Ltd (TITANBIO) last traded at ₹384, a market capitalisation of ₹1,586 crore, on a P/E of 46.8. Over the past 52 weeks the stock has ranged between ₹93.4 and ₹556. Titan Biotech Ltd last reported results for the quarter ended Jun 2026, with sales of ₹59 crore and net profit of ₹11 crore. Figures are as of 25 Aug 2026 and are not real time.
Titan Biotech Ltd share price and key metrics
Metrics as of 25 Aug 2026. Not real time.
Titan Biotech Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹59 cr, up 28.3% from ₹46 cr a year earlier. Net profit was ₹11 cr, up 57.1% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 40 | 38 | 35 | 46 | 54 | 57 | 49 | 59 |
| Expenses | 32 | 33 | 31 | 38 | 45 | 46 | 39 | 47 |
| Operating profit | 8 | 5 | 5 | 9 | 9 | 11 | 10 | 12 |
| OPM % | 19% | 13% | 13% | 19% | 17% | 19% | 20% | 21% |
| Other income | 0 | 2 | 1 | 1 | 1 | 1 | 2 | 2 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | 7 | 5 | 5 | 8 | 9 | 11 | 10 | 13 |
| Tax % | 25% | 26% | 25% | 24% | 26% | 26% | 36% | 26% |
| Net profit | 7 | 4 | 4 | 7 | 8 | 9 | 7 | 11 |
| EPS (₹) | 1.62 | 1.06 | 0.98 | 1.66 | 1.88 | 2.07 | 1.63 | 2.63 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Titan Biotech Ltd annual results
| ₹ crore | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|
| Sales | 142 | 124 | 144 | 164 | 156 | 206 | 219 |
| Operating profit | 46 | 31 | 30 | 34 | 25 | 39 | 42 |
| OPM % | 32% | 25% | 21% | 21% | 16% | 19% | 19% |
| Net profit | 32 | 22 | 25 | 25 | 22 | 30 | 34 |
| EPS (₹) | 7.35 | 5.25 | 6.01 | 6.02 | 5.21 | 7.23 | 8.21 |
TTM is the trailing twelve months to the most recent quarter.
Titan Biotech Ltd growth and returns
- 10 Years
- 16%
- 5 Years
- 8%
- 3 Years
- 13%
- TTM
- 37%
- 10 Years
- 33%
- 5 Years
- 0%
- 3 Years
- 6%
- TTM
- 54%
- 10 Years
- 49%
- 5 Years
- 42%
- 3 Years
- 77%
- 1 Year
- 311%
- 10 Years
- 22%
- 5 Years
- 20%
- 3 Years
- 18%
- Last Year
- 18%
Titan Biotech Ltd shareholding pattern
Promoters held 55.78% at Jun 2026, broadly unchanged since Jun 2025. DIIs 0.01%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 55.87% | 55.87% | 55.87% | 55.87% | 55.78% | 55.78% | 55.78% | 55.78% |
| DIIs | 0.00% | 0.00% | 0.01% | 0.03% | 0.03% | 0.03% | 0.03% | 0.01% |
| Public | 44.13% | 44.12% | 44.11% | 44.10% | 44.19% | 44.19% | 44.19% | 44.21% |
| No. of shareholders | 15,700 | 16,038 | 16,370 | 16,328 | 16,040 | 16,367 | 17,457 | 18,671 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Titan Biotech Ltd corporate filings
- Newspaper publication of the Unaudited Financial Results (Standalone & Consolidated) for quarter ended June 30, 2026Company Updatelow impact
Cruxal's analysis: Titan Biotech Limited has released its unaudited financial results for the quarter ended…
Read the full analysis - Unaudited Financial Results along with the limited review report from the statutory Auditor of the Company for the quarter ended June 2026Resulthigh impact
Cruxal's analysis: Titan Biotech Limited has announced its unaudited financial results for the quarter ended…
Read the full analysis - Titan Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2026 ,inter alia, to consider and approve the standalone and consolidated ....Board Meetinglow impact
Cruxal's analysis: Titan Biotech Limited has formally intimated the BSE regarding a Board of Directors…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Track Titan Biotech Ltd
Cruxal reads every Titan Biotech Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.